News - Blood Biomarker May Predict ADHD and Mood Disorders: Presented at APA
Blood Biomarker May Predict ADHD and Mood Disorders: Presented at APA
By Paula Moyer
SAN DIEGO, CA -- May 25, 2007 -- Cell membrane potential may help psychiatrists differentiate attention deficit hyperactivity disorder (ADHD), bipolar disorder, and possibly major depressive disorder, according to investigators who presented their findings here at the American Psychiatric Association 2007 Annual Meeting (APA).
This physiologic property of cells differs among these disorders and is also differentiated from that seen in healthy controls, according to investigators Sharon A. Murphy, MD, and Douglas Woodruff, MD, psychiatrists in private practice in Baltimore, Maryland, United States.
Cell membrane potential is the electrical charge across the membrane, based on the potassium gradient and the chlorine gradient. When cells are placed in a potassium-free buffer, the assay used in the test, cells are stressed. Abnormal regulation of ion distribution and variability in the functioning of the sodium-potassium pump within cells is known to be associated with bipolar I disorder and may also be a hallmark of ADHD, according to Drs. Murphy and Woodruff.
"While using the membrane potential assay to identify bipolar I disorder, we were intrigued by data that suggested this membrane potential test is also sensitive to presumed malfunctioning of the sodium-potassium pump in ADHD," the authors reported.
[...]
The resulting test gave clinicians "a very clear and distinct difference among the controls, people with ADHD, and people with bipolar I disorder," said Dr. Woodruff. The average membrane potential ratio was 0.8, and the average ratio for ADHD was 1.1; the mean ratio in controls was 0.9.
"We used this blood test to direct treatment decisions, and then used the gold standard of patient response to medication to confirm the test results," said Dr. Woodruff. "We had a response rate of 95%."
"We now wonder if patients who had not responded in the past may have been misdiagnosed," Dr. Murphy said. "The test was more accurate than we were."
The investigators thought that this assay, if validated in further studies, could help psychiatrists be more precise the differential diagnosis between ADHD and bipolar I disorder, and that it could also help them differentiate between unipolar recurrent depression and the depressive phase of bipolar I disorder.
Blood Biomarker May Predict ADHD and Mood Disorders: Presented at APA
By Paula Moyer
SAN DIEGO, CA -- May 25, 2007 -- Cell membrane potential may help psychiatrists differentiate attention deficit hyperactivity disorder (ADHD), bipolar disorder, and possibly major depressive disorder, according to investigators who presented their findings here at the American Psychiatric Association 2007 Annual Meeting (APA).
This physiologic property of cells differs among these disorders and is also differentiated from that seen in healthy controls, according to investigators Sharon A. Murphy, MD, and Douglas Woodruff, MD, psychiatrists in private practice in Baltimore, Maryland, United States.
Cell membrane potential is the electrical charge across the membrane, based on the potassium gradient and the chlorine gradient. When cells are placed in a potassium-free buffer, the assay used in the test, cells are stressed. Abnormal regulation of ion distribution and variability in the functioning of the sodium-potassium pump within cells is known to be associated with bipolar I disorder and may also be a hallmark of ADHD, according to Drs. Murphy and Woodruff.
"While using the membrane potential assay to identify bipolar I disorder, we were intrigued by data that suggested this membrane potential test is also sensitive to presumed malfunctioning of the sodium-potassium pump in ADHD," the authors reported.
[...]
The resulting test gave clinicians "a very clear and distinct difference among the controls, people with ADHD, and people with bipolar I disorder," said Dr. Woodruff. The average membrane potential ratio was 0.8, and the average ratio for ADHD was 1.1; the mean ratio in controls was 0.9.
"We used this blood test to direct treatment decisions, and then used the gold standard of patient response to medication to confirm the test results," said Dr. Woodruff. "We had a response rate of 95%."
"We now wonder if patients who had not responded in the past may have been misdiagnosed," Dr. Murphy said. "The test was more accurate than we were."
The investigators thought that this assay, if validated in further studies, could help psychiatrists be more precise the differential diagnosis between ADHD and bipolar I disorder, and that it could also help them differentiate between unipolar recurrent depression and the depressive phase of bipolar I disorder.
Comments